Publication | Open Access

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Hematological MalignancyDexamethasone Versus LenalidomideMedicineHematologyMyeloid NeoplasiaPathologyMultiple MyelomaOncologyRadiation OncologyOverall Survival ResultsHealth Sciences